Benchmark Capital Advisors raised its holdings in shares of Chembio Diagnostics Inc (NASDAQ:CEMI) by 101.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 66,417 shares of the company’s stock after buying an additional 33,517 shares during the quarter. Benchmark Capital Advisors’ holdings in Chembio Diagnostics were worth $545,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Goldman Sachs Group Inc. acquired a new stake in Chembio Diagnostics during the 2nd quarter valued at approximately $151,000. 33.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of Chembio Diagnostics Inc (NASDAQ:CEMI) opened at $7.75 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.19 and a current ratio of 3.54. Chembio Diagnostics Inc has a 12 month low of $5.05 and a 12 month high of $9.20. The company has a market cap of $95.59, a P/E ratio of -13.60 and a beta of 1.14.
WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2018/02/09/chembio-diagnostics-inc-cemi-shares-bought-by-benchmark-capital-advisors.html.
About Chembio Diagnostics
Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.
Want to see what other hedge funds are holding CEMI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chembio Diagnostics Inc (NASDAQ:CEMI).
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.